X36

SI-8011

X36, >98% (HPLC)

IUPAC Name : 6-((1-(2-Chloro-4-(furan-2-yl)benzyl)-4-hydroxypiperidin-4-yl)methyl)-3-(4-fluorophenyl)-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a potent and selective USP7 inhibitor from a series of N‑benzylpiperidinol derivatives, featuring nanomolar USP7 inhibition (X20 and X26: IC₅₀ = 7.6 and 8.2 nM) with a distinct binding mode confirmed by crystallography. Among them, X36 shows good oral PK in rats (F = 40.8%, t_1/2= 3.5 h) and delivers significant antitumor efficacy in the MC38 colon cancer syngeneic model. Its activity is associated with enhanced infiltration of CD8⁺ T cells, NK cells, and NKT cells, along with reduced Tregs and MDSCs, indicating immune‑microenvironment modulation. Overall, this series—especially X36—supports the development of USP7 inhibitors as promising cancer immunotherapy agents.

References : Li X. et al.: J. Med. Chem., 65(24), 16622-16639, 2022.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.